Recursion Pharmaceuticals (RXRX) closed at $6.36 in the latest trading session, marking a +0.47% move from the prior day. This change outpaced the S&P 500's 0.22% gain on the day. Meanwhile, the Dow lost 0.33%, and the Nasdaq, a tech-heavy index, added 0.76%.Coming into today, shares of the biotechnology company had lost 8.13% in the past month. In that same time, the Medical sector lost 3.79%, while the S&P 500 gained 1.47%.The investment community will be closely monitoring the performance of Recursion Ph ...

Wood has a stake in this stock, but it's hardly an "all-in" bet. Artificial intelligence (AI) is changing the way we do business. Companies are racing to implement it in umpteen different ways, knowing that the most successful will reap immense financial benefits. That's why investors are also searching for the most exciting AI stocks, but picking the right one might not be easy. How about getting some inspiration from famous investors? Cathie Wood, the CEO of Ark Invest, has several AI stocks in her invest ...

This clinical-stage drugmaker's AI platform could speed up the development process, but initial results were disappointing. The artificial intelligence (AI) revolution is pushing up the overall stock market, but not every AI stock is performing well. Shares of Recursion Pharmaceuticals (RXRX 1.51%) are down by more than half from a peak they set this spring. The start-up drugmaker disappointed investors with lackluster results for its lead candidate in September. Luckily, it has a deep pipeline of less-adva ...

These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead. Artificial intelligence (AI) is poised to revolutionize the global economy. By 2030, AI could add $15.7 trillion to worldwide GDP, a 26% increase, according to a report by PwC, a leading global consulting firm. This projected growth is expected to stem from significant productivity gains and increased consumer demand. A study by the World Economic Forum, an international organization ...

Recursion Pharmaceuticals (RXRX) closed at $6.67 in the latest trading session, marking a -1.91% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.28%. Meanwhile, the Dow gained 0.15%, and the Nasdaq, a tech-heavy index, added 0.15%. The biotechnology company's shares have seen a decrease of 12.93% over the last month, not keeping up with the Medical sector's gain of 0.38% and the S&P 500's gain of 2%. Market participants will be closely following the financial results ...

Recursion Pharmaceuticals (RXRX) shares plunged 16.6% on Sept. 3 after announcing mixed results from a mid-stage study evaluating the safety, tolerability and efficacy of its lead candidate, REC-994, an orally bioavailable, superoxide scavenger small molecule, for symptomatic cerebral cavernous malformation (CCM) patients. Recursion's SYCAMORE Study Meets Primary Goal but Efficacy Lags Recursion reported that its phase II SYCAMORE study met the primary endpoint of safety and tolerability in CCM patients tre ...

Don't expect Buffett to invest in this stock tomorrow, but it has the potential to eventually be a stock he would consider. Recursion Pharmaceuticals (RXRX 0.54%) doesn't look like a stock that legendary investor Warren Buffett would usually be interested in. It's in the biotech industry, which tends to be volatile and often difficult to understand, without significant recurring revenue or any profits for many of the newer stocks in the sector. To complicate matters further, Recursion is engaged in the emer ...

SALT LAKE CITY, Aug. 08, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Recursion (Nasdaq: RXRX), please note that in the first bullet under "Additional Corporate Updates", the company's conference call should have been mentioned as having already taken place earlier this morning, rather than coming up later this afternoon as previously stated. The corrected bullet should have read: L(earnings) Call: We will host a L(earnings) Call on Aug 8, 2024 at 8:30 am Eastern Tim ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -14.29%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.43 per share when it actually produced a loss of $0.39, delivering a surprise of 9.30%. Over the last four quarters ...

Core Insights - Recursion, a clinical stage TechBio company, is set to provide business updates and Q2 2024 financial results on August 8, 2024, before market opening [1] - The company will host a public earnings call on the same day, allowing audience interaction and questions [1] Company Overview - Recursion specializes in decoding biology to industrialize drug discovery, utilizing its proprietary Recursion OS platform [1] - The platform integrates diverse technologies and maintains one of the largest biological and chemical datasets globally [1] - Recursion employs advanced machine-learning algorithms to identify trillions of relationships in biology and chemistry, free from human bias [1] - The company conducts millions of wet lab experiments weekly and operates one of the world's most powerful supercomputers [1] - Recursion is headquartered in Salt Lake City and is a founding member of BioHive, a collective for Utah's life sciences industry [1]